Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 64742
A duodenal ulcer is a peptic ulcer that develops in the first part of the small intestine (duodenum).
IPSCIO Record ID: 314125
MovantikÂ® is a prescription medicine used to treat constipation that is caused by prescription pain medicines called opioids.
MovantikÂ® is a proprietary once-daily oral PAMORA approved by the U.S. Food and Drug Administration for the treatment of OIC in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation
RHB-204 is used for pulmonary nontuberculous mycobacteria (NTM) infections. Pulmonary nontuberculous mycobacteria (NTM) disease is a chronic and debilitating lung disease caused by ubiquitous environmental bacteria, found in the soil as well as natural and engineered water systems.
Licensor is a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.
IPSCIO Record ID: 28650
Stomach ulcers, also known as gastric ulcers, are open sores that develop on the lining of the stomach. Ulcers can also occur in part of the intestine just beyond the stomach. These are known as duodenal ulcers.
IPSCIO Record ID: 7295
RHB-104 for the treatment of Crohn's disease; RHB-105 for the treatment of Helicobacter pylori infection, a major cause of peptic ulcer disease; and RHB-106 for bowel preparation prior to abdominal procedures such as surgery or colonoscopy.
The Licensor further transferred to the Licensee products in process, product samples and raw materials.
The Agreement excluded from the transfer the rights to two other products of the Licensor that are not related to RHB-104, RHB-105 and RHB-106.
To the extent that the intellectual property associated with these two other products shall be required for the research, development, manufacture, registration, import/export, use, commercialization, distribution, sale and/or offer for sale of any of RHB-104, RHB-105 and RHB-106, the Licensor granted the Licensee an exclusive worldwide assignable right to such intellectual property for such purposes. The closing under this Agreement occurred on August 26, 2010.
IPSCIO Record ID: 29176
IPSCIO Record ID: 463
As part of the asset transfer, royalty bearing options are being made available to current Noteholder of the entity-to-be-acquired as well as the Series B Preferred Stockholders of the acquired company. The royalties will be based upon sales of the drugs Helivax and Activax.
Activax is a combined multivalent vaccine for the prevention of Traveler's diarrheal diseases.